리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 07월
페이지 정보:영문 278 Pages
라이선스 & 가격 (부가세 별도)
한글목차
폐경후 골다공증 치료 세계 시장은 2030년까지 124억 달러에 달할 전망
2024년에 98억 달러로 추정되는 폐경후 골다공증 치료 세계 시장은 2024-2030년 분석 기간에 CAGR 4.0%로 성장하여 2030년에는 124억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 비스포스포네이트는 CAGR 5.2%를 기록하며 분석 기간 종료시에는 35억 달러에 달할 것으로 예측됩니다. 비타민 D3 분야의 성장률은 분석 기간 동안 CAGR 3.0%로 추정됩니다.
미국 시장은 27억 달러로 추정, 중국은 CAGR 7.5%로 성장 예측
미국의 폐경후 골다공증 치료 시장은 2024년에는 27억 달러에 달할 것으로 추정됩니다. 세계 2위 경제 대국인 중국은 2024년부터 2030년 분석 기간 동안 CAGR 7.5%로 성장하여 2030년에는 25억 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.6%와 3.1%로 예측됩니다. 유럽에서는 독일이 CAGR 2.3%로 성장할 것으로 예측됩니다.
세계의 폐경후 골다공증 치료 시장 - 주요 동향과 촉진요인 정리
폐경후 골다공증 치료는 왜 고령화 사회에 필수적인가?
폐경후 골다공증(PMO)은 폐경 후 에스트로겐 결핍으로 인해 전 세계 수백만 명의 여성들이 앓고 있는 진행성 뼈 질환으로, 뼈의 취약성과 골절 위험을 증가시키는 질환입니다. 인구의 고령화와 평균수명의 연장으로 폐경후 골다공증은 특히 북미, 유럽, 아시아태평양에서 공중보건의 큰 문제로 대두되고 있습니다. 골다공증은 운동 능력, 독립성, 의료 비용에 큰 영향을 미치기 때문에 효과적이고 혁신적인 골다공증 치료제에 대한 수요가 증가하고 있습니다.
골다공증과 관련된 골절, 특히 고관절, 척추, 손목 골절의 유병률이 증가함에 따라 조기 진단, 예방, 치료가 중요시되고 있습니다. 뼈 건강과 골절 예방에 대한 인식이 높아짐에 따라 점점 더 많은 여성들이 약리 요법, 생활 습관 개선, 첨단 뼈 건강 모니터링 기술을 통한 의학적 개입을 원하고 있습니다. 폐경후 골다공증 치료 시장은 검진 프로그램 개선, 정부의 헬스케어 이니셔티브, 의약품 개발의 발전으로 확대되고 있습니다.
기술의 발전은 골다공증 치료 옵션을 어떻게 개선하고 있는가?
약리학, 생명공학, 디지털 헬스 솔루션 분야의 혁신은 폐경후 골다공증 관리를 혁신적으로 변화시키고 있으며, 보다 효과적이고 개인화되고 편리한 치료를 가능하게 하고 있습니다. 가장 중요한 진전 중 하나는 골절 예방과 환자 순응도를 향상시킬 수 있는 골다공증 치료제인 단클론항체, 선택적 에스트로겐 수용체 조절제(SERM), 골형성제를 포함한 차세대 골다공증 치료제의 개발입니다.
그 중에서도 데노수맙(Prolia), 로모소주맙(이브니티) 등의 단클론항체 치료제는 골흡수의 표적화 억제와 골형성 촉진을 가져와 치료의 전망을 바꾸고 있습니다. 이들 생물학적 제제는 기존 비스포스포네이트 제제보다 우수한 효과를 보이며, 주사를 통한 간편한 투여 스케줄로 척추 골절 및 비척추 골절의 위험을 감소시킵니다. 마찬가지로, 테리파라타이드(Forteo)나 아바로파라타이드(Tymlos)와 같은 단백 동화 약물의 개발로 뼈 재생을 촉진해야 하는 고위험군 환자들에게 새로운 치료 옵션이 도입되었습니다.
디지털 헬스 및 웨어러블 기술의 발전은 골다공증 관리에도 혁명을 불러일으키고 있습니다. 골밀도 추적 앱, AI 기반 골절 위험 평가 도구, 원격 환자 모니터링 시스템 등 스마트 건강 모니터링 기기는 의사가 실시간 뼈 건강 데이터를 기반으로 개인화된 치료 계획을 세우는 데 도움을 주고 있습니다. 또한, 원격의료와 가상 진료는 특히 농촌이나 의료 서비스가 부족한 지역의 고령 환자들에게 골다공증 치료를 더욱 친숙하게 만들어주고 있습니다.
폐경후 골다공증 치료제의 성장을 촉진하는 시장 동향은?
폐경후 골다공증 치료 시장에서 가장 두드러진 트렌드 중 하나는 생물학적 제제와 표적 치료제의 채택이 증가하고 있다는 점입니다. 비스포스포네이트의 장기 사용과 비정형 골절 및 턱뼈 괴사(ONJ)와 같은 잠재적 위험에 대한 우려가 커지면서 많은 의료진들이 환자들을 우수한 안전성 프로파일을 가진 새로운 생물학적 제제 치료제로 전환하고 있습니다. 이러한 변화로 인해 단클론항체 및 단백질 동화제 분야에서 강력한 시장 성장을 촉진하고 있습니다.
골다공증 진단에 인공지능(AI)과 머신러닝(ML)의 통합은 시장에 영향을 미치는 또 다른 주요 트렌드입니다. AI를 활용한 뼈 건강 스크리닝 알고리즘과 예측 분석은 골밀도(BMD) 스캔, 유전자 마커, 환자의 생활습관 데이터를 분석하여 골다공증을 조기에 발견할 수 있게 합니다. 이러한 발전은 적극적인 치료 시작과 개별화된 치료 조정을 촉진하여 환자의 치료 결과와 순응도를 향상시키고 있습니다.
또 다른 중요한 트렌드는 병용요법과 다중 표적 치료 전략의 중요성입니다. 연구팀은 골흡수 억제와 골형성 촉진을 모두 강화하여 단독 요법보다 골절 예방 효과를 높일 수 있는 새로운 약물 조합을 모색하고 있습니다. 또한, 약리학적 치료와 함께 비타민 D와 칼슘 보충제의 사용이 증가하여 치료 효과와 환자의 순응도가 향상되고 있습니다.
골다공증 인식 개선 프로그램 및 정부의 헬스케어 정책 확대도 시장 성장을 견인하고 있습니다. 많은 국가에서 골절 연락 서비스(FLS)와 골다공증 검진 프로그램을 통해 위험에 처한 여성들을 조기에 발견하고 치료할 수 있도록 하고 있습니다. 골다공증 치료제 및 뼈 건강검진에 대한 급여화 정책과 보험 적용 확대는 치료 도입률을 더욱 높이고 있습니다.
폐경후 골다공증 치료 시장의 성장을 촉진하는 요인은 무엇인가?
폐경후 골다공증 치료 시장의 성장은 세계 인구의 고령화, 골절 발생률 증가, 약물 치료의 발전 등 여러 가지 요인에 의해 이루어지고 있습니다. 특히 일본, 중국, 미국, 유럽 등 인구통계학적 고령화가 빠르게 진행되고 있는 지역에서는 폐경 후 여성의 수가 전 세계적으로 증가하고 있는 것이 주요 요인 중 하나입니다. 50세 이상 여성 3명 중 1명이 골다공증과 관련된 골절로 고통받는 것으로 추정되며, 예방 및 치료적 개입에 대한 수요가 가속화되고 있습니다.
또 다른 큰 성장 요인은 골다공증 치료제 연구개발(R&D)의 확대입니다. 제약사들은 이중작용 치료제, 줄기세포를 이용한 골재생 치료제, 부작용이 적고 효과가 높은 유전자 표적 치료제 등 차세대 골다공증 치료제에 많은 투자를 하고 있습니다. 골다공증 치료에 바이오시밀러가 도입되면서 첨단 치료제를 보다 저렴하게 이용할 수 있게 되었고, 신흥 경제국에서 시장 개척이 진행되고 있습니다.
골다공증 관리를 위한 디지털 헬스 솔루션의 채택이 증가하고 있는 것도 시장 확대에 기여하고 있습니다. 모바일 건강(mHealth) 앱, 웨어러블 골밀도 측정기, AI 기반 위험 평가 도구의 등장으로 환자와 의사는 골다공증을 보다 효과적으로 추적하고 관리할 수 있게 되었습니다. 또한, 원격의료 서비스와 원격 환자 모니터링 프로그램은 특히 의료 인프라가 부족한 지역에서 골다공증 치료를 보다 쉽게 접할 수 있도록 돕고 있습니다.
마지막으로, 골다공증 예방과 생활습관 개선에 대한 인식이 높아지면서 조기 치료의 도입이 촉진되고 있습니다. 체중을 지탱하는 운동, 영양 보충, 생활습관 개선을 장려하는 공중보건 캠페인은 여성들에게 조기 골다공증 검진 및 예방 치료를 받도록 촉구하고 있습니다. 골다공증이 심각한 만성질환이라는 인식이 확산됨에 따라 의료 서비스 제공자는 예방적 뼈 건강 관리를 우선시하고 있으며, 골다공증 치료에 대한 장기적인 수요를 증가시키고 있습니다.
골다공증에 대한 부담이 계속 증가하는 가운데, 생물학적 제제의 발전, 디지털 건강 혁신, 골절 예방 및 조기 개입을 위한 전 세계적인 노력으로 폐경후 골다공증 치료 시장이 확대될 것으로 예상됩니다.
부문
치료 유형(비스포스포네이트, 비타민 D3, 에스트로겐 작용제/길항제, 호르몬 대체요법, 부갑상선호르몬 요법, 기타 치료 유형), 유통 채널(병원 약국, 소매 약국, 기타 유통 채널)
조사 대상 기업 사례
Allergan plc
Amgen Inc.
Cipla Inc.
Daiichi Sankyo Company, Limited
Eisai Co., Ltd.
Eli Lilly and Company
Entera Bio Ltd.
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Novo Nordisk A/S
Pfizer Inc.
Radius Health, Inc.
Sanofi S.A.
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Ltd.
Teva Pharmaceutical Industries Ltd.
UCB S.A.
AI 통합
우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.
Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트
기타 중동
아프리카
제4장 경쟁
ksm
영문 목차
영문목차
Global Postmenopausal Osteoporosis Treatment Market to Reach US$12.4 Billion by 2030
The global market for Postmenopausal Osteoporosis Treatment estimated at US$9.8 Billion in the year 2024, is expected to reach US$12.4 Billion by 2030, growing at a CAGR of 4.0% over the analysis period 2024-2030. Bisphosphonates, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$3.5 Billion by the end of the analysis period. Growth in the Vitamin D3 segment is estimated at 3.0% CAGR over the analysis period.
The U.S. Market is Estimated at US$2.7 Billion While China is Forecast to Grow at 7.5% CAGR
The Postmenopausal Osteoporosis Treatment market in the U.S. is estimated at US$2.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 7.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.
Why Is Postmenopausal Osteoporosis Treatment Essential for Aging Populations?
Postmenopausal osteoporosis (PMO) is a progressive bone disease that affects millions of women worldwide due to estrogen deficiency following menopause, leading to increased bone fragility and fracture risk. With aging populations and longer life expectancy, postmenopausal osteoporosis has become a major public health concern, particularly in North America, Europe, and Asia-Pacific, where a rising number of postmenopausal women are at risk of osteoporotic fractures. The condition significantly impacts mobility, independence, and healthcare costs, driving the demand for effective and innovative osteoporosis treatments.
The increasing prevalence of osteoporosis-related fractures, especially hip, spine, and wrist fractures, has led to a greater focus on early diagnosis, prevention, and treatment. As awareness of bone health and fracture prevention grows, more women are seeking medical intervention through pharmacological therapies, lifestyle modifications, and advanced bone health monitoring technologies. The market for postmenopausal osteoporosis treatments is expanding due to improved screening programs, government healthcare initiatives, and advancements in drug development.
How Are Technological Advancements Improving Osteoporosis Treatment Options?
Innovations in pharmacology, biotechnology, and digital health solutions are transforming the management of postmenopausal osteoporosis, making treatments more effective, personalized, and convenient. One of the most significant advancements is the development of next-generation osteoporosis drugs, including monoclonal antibodies, selective estrogen receptor modulators (SERMs), and bone-forming agents that offer better fracture protection and improved patient adherence.
Among the latest breakthroughs, monoclonal antibody therapies such as Denosumab (Prolia) and Romosozumab (Evenity) are changing the treatment landscape by providing targeted inhibition of bone resorption and enhanced bone formation. These biologic agents offer superior efficacy compared to traditional bisphosphonates, reducing the risk of vertebral and non-vertebral fractures with convenient injection-based dosing schedules. Similarly, the development of anabolic agents like Teriparatide (Forteo) and Abaloparatide (Tymlos) has introduced new treatment options for high-risk patients requiring accelerated bone regeneration.
The rise of digital health and wearable technology is also revolutionizing osteoporosis management. Smart health monitoring devices, including bone density tracking apps, AI-driven fracture risk assessment tools, and remote patient monitoring systems, are helping physicians tailor personalized treatment plans based on real-time bone health data. Additionally, telemedicine and virtual consultations are making osteoporosis care more accessible, particularly for elderly patients in rural and underserved regions.
What Market Trends Are Driving the Growth of Postmenopausal Osteoporosis Treatment?
One of the most prominent trends in the postmenopausal osteoporosis treatment market is the increasing adoption of biologics and targeted therapies. With growing concerns about long-term bisphosphonate use and its potential risks, such as atypical fractures and osteonecrosis of the jaw (ONJ), many healthcare providers are transitioning patients to novel biologic treatments with superior safety profiles. This shift is driving strong market growth in the monoclonal antibody and anabolic drug segments.
The integration of artificial intelligence (AI) and machine learning (ML) in osteoporosis diagnostics is another key trend influencing the market. AI-powered bone health screening algorithms and predictive analytics are enabling early detection of osteoporosis by analyzing bone mineral density (BMD) scans, genetic markers, and patient lifestyle data. This advancement is facilitating proactive treatment initiation and personalized therapy adjustments, improving patient outcomes and adherence rates.
Another significant trend is the emphasis on combination therapies and multi-target treatment strategies. Researchers are exploring new drug combinations that enhance both bone resorption inhibition and bone formation stimulation, offering greater fracture protection than monotherapy. Additionally, the increasing use of vitamin D and calcium supplementation, along with pharmacological treatments, is improving treatment effectiveness and patient compliance.
The expansion of osteoporosis awareness programs and government healthcare policies is also shaping market growth. Many countries are implementing fracture liaison services (FLS) and osteoporosis screening programs to ensure early detection and treatment of at-risk women. Reimbursement policies and insurance coverage expansions for osteoporosis medications and bone health screenings are further encouraging higher treatment adoption rates.
What Factors Are Driving the Growth of the Postmenopausal Osteoporosis Treatment Market?
The growth in the postmenopausal osteoporosis treatment market is driven by several factors, including an aging global population, rising fracture incidence, and advancements in drug therapies. One of the primary drivers is the growing number of postmenopausal women worldwide, particularly in regions with rapidly aging demographics, such as Japan, China, the U.S., and Europe. With one in three women over the age of 50 estimated to suffer from an osteoporosis-related fracture, the demand for preventive and therapeutic interventions is accelerating.
Another major growth factor is the expansion of research and development (R&D) in osteoporosis drug discovery. Pharmaceutical companies are heavily investing in new-generation osteoporosis drugs, including dual-action therapies, stem cell-based bone regeneration treatments, and gene-targeted medications that promise higher efficacy with fewer side effects. The introduction of biosimilars for osteoporosis treatments is also making advanced therapies more affordable and accessible, increasing market penetration in developing economies.
The rising adoption of digital health solutions for osteoporosis management is contributing to market expansion. The availability of mobile health (mHealth) apps, wearable bone density monitors, and AI-driven risk assessment tools is empowering patients and physicians to track and manage osteoporosis more effectively. Additionally, telehealth services and remote patient monitoring programs are making osteoporosis care more accessible, particularly in regions with limited healthcare infrastructure.
Lastly, the increasing awareness of osteoporosis prevention and lifestyle interventions is driving early treatment adoption. Public health campaigns promoting weight-bearing exercises, nutritional supplementation, and lifestyle modifications are encouraging women to seek early osteoporosis screenings and preventive treatments. With the growing recognition of osteoporosis as a serious chronic condition, healthcare providers are prioritizing proactive bone health management, boosting long-term demand for osteoporosis therapies.
As the burden of osteoporosis continues to rise, the postmenopausal osteoporosis treatment market is expected to expand, driven by biologic drug advancements, digital health innovations, and global initiatives for fracture prevention and early intervention.
SCOPE OF STUDY:
The report analyzes the Postmenopausal Osteoporosis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Treatment Type (Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy, Other Treatment Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 32 Featured) -
Allergan plc
Amgen Inc.
Cipla Inc.
Daiichi Sankyo Company, Limited
Eisai Co., Ltd.
Eli Lilly and Company
Entera Bio Ltd.
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Novo Nordisk A/S
Pfizer Inc.
Radius Health, Inc.
Sanofi S.A.
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Ltd.
Teva Pharmaceutical Industries Ltd.
UCB S.A.
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Tariff Impact on Global Supply Chain Patterns
Postmenopausal Osteoporosis Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Prevalence of Postmenopausal Osteoporosis Spurring Demand for Advanced Treatment Options
Increasing Awareness of Osteoporosis Among Women Drives the Adoption of Preventive Care and Treatment Solutions
Growth in the Elderly Population Intensifies the Need for Effective Postmenopausal Osteoporosis Therapies
Shift Towards Personalized Medicine Expands Opportunities for Tailored Postmenopausal Osteoporosis Treatments
Increased Investment in Research and Development Accelerates Innovation in Postmenopausal Osteoporosis Treatment
Emergence of New Drug Classifications, Such as Monoclonal Antibodies, Expands Treatment Options
Demand for Injectable Medications for Postmenopausal Osteoporosis Spurs Market Expansion
Regulatory Approval of New Therapies and Treatment Modalities Accelerates the Market Growth
Advances in Bone Mineral Density Monitoring Technology Strengthen Market Penetration of Postmenopausal Osteoporosis Treatments
Rising Healthcare Expenditure in Developing Markets Increases Access to Osteoporosis Treatment Solutions
Growing Popularity of Combination Therapies Offers New Growth Opportunities for Treatment Providers
Increasing Preference for Non-Surgical Treatment Solutions Enhances the Market for Postmenopausal Osteoporosis Drugs
Innovations in Delivery Systems, Such as Oral and Subcutaneous Therapies, Strengthen the Business Case for New Treatments
Integration of Digital Health Tools in Osteoporosis Care Generates New Pathways for Disease Management and Monitoring
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Postmenopausal Osteoporosis Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Postmenopausal Osteoporosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for Bisphosphonates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Vitamin D3 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Vitamin D3 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Vitamin D3 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Estrogen Agonist / Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Estrogen Agonist / Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Estrogen Agonist / Antagonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Hormone Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Hormone Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Hormone Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Parathyroid Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Parathyroid Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Parathyroid Hormone Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 22: World 15-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 25: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 28: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 30: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 31: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Postmenopausal Osteoporosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 32: USA Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 33: USA Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 34: USA 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 35: USA Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 36: USA Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 37: USA 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
CANADA
TABLE 38: Canada Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: Canada Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 40: Canada 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 41: Canada Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 42: Canada Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 43: Canada 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
JAPAN
Postmenopausal Osteoporosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 44: Japan Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: Japan Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 46: Japan 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 47: Japan Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 48: Japan Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 49: Japan 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
CHINA
Postmenopausal Osteoporosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 50: China Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: China Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 52: China 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 53: China Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 54: China Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 55: China 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
EUROPE
Postmenopausal Osteoporosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 56: Europe Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Postmenopausal Osteoporosis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 58: Europe 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 59: Europe Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 60: Europe Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 61: Europe 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 62: Europe Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: Europe Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 64: Europe 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
FRANCE
Postmenopausal Osteoporosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 65: France Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: France Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 67: France 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 68: France Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: France Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 70: France 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
GERMANY
Postmenopausal Osteoporosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 71: Germany Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: Germany Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 73: Germany 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 74: Germany Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: Germany Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 76: Germany 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
ITALY
TABLE 77: Italy Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 78: Italy Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 79: Italy 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 80: Italy Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: Italy Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 82: Italy 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
UNITED KINGDOM
Postmenopausal Osteoporosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 83: UK Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: UK Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 85: UK 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 86: UK Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: UK Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 88: UK 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
SPAIN
TABLE 89: Spain Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: Spain Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 91: Spain 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 92: Spain Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Spain Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 94: Spain 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
RUSSIA
TABLE 95: Russia Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 96: Russia Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 97: Russia 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 98: Russia Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Russia Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 100: Russia 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 102: Rest of Europe Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 103: Rest of Europe 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 105: Rest of Europe Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 106: Rest of Europe 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Postmenopausal Osteoporosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for Postmenopausal Osteoporosis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 109: Asia-Pacific 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 111: Asia-Pacific Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 112: Asia-Pacific 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 114: Asia-Pacific Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 115: Asia-Pacific 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
AUSTRALIA
Postmenopausal Osteoporosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 116: Australia Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 117: Australia Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 118: Australia 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 119: Australia Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 120: Australia Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 121: Australia 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
INDIA
Postmenopausal Osteoporosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 122: India Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 123: India Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 124: India 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 125: India Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 126: India Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 127: India 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
SOUTH KOREA
TABLE 128: South Korea Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 129: South Korea Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 130: South Korea 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 131: South Korea Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 132: South Korea Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 133: South Korea 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 135: Rest of Asia-Pacific Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 138: Rest of Asia-Pacific Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
LATIN AMERICA
Postmenopausal Osteoporosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 140: Latin America Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 141: Latin America Historic Review for Postmenopausal Osteoporosis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 142: Latin America 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
TABLE 143: Latin America Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 144: Latin America Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 145: Latin America 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 146: Latin America Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 147: Latin America Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 148: Latin America 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
ARGENTINA
TABLE 149: Argentina Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 150: Argentina Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 151: Argentina 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 152: Argentina Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 153: Argentina Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 154: Argentina 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
BRAZIL
TABLE 155: Brazil Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 156: Brazil Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 157: Brazil 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 158: Brazil Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 159: Brazil Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 160: Brazil 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
MEXICO
TABLE 161: Mexico Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 162: Mexico Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 163: Mexico 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 164: Mexico Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 165: Mexico Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 166: Mexico 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 168: Rest of Latin America Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 169: Rest of Latin America 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 171: Rest of Latin America Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 172: Rest of Latin America 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
MIDDLE EAST
Postmenopausal Osteoporosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 173: Middle East Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 174: Middle East Historic Review for Postmenopausal Osteoporosis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 175: Middle East 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
TABLE 176: Middle East Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 177: Middle East Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 178: Middle East 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 179: Middle East Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 180: Middle East Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 181: Middle East 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
IRAN
TABLE 182: Iran Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 183: Iran Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 184: Iran 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 185: Iran Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 186: Iran Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 187: Iran 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
ISRAEL
TABLE 188: Israel Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 189: Israel Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 190: Israel 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 191: Israel Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 192: Israel Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 193: Israel 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
SAUDI ARABIA
TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 195: Saudi Arabia Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 196: Saudi Arabia 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 198: Saudi Arabia Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 199: Saudi Arabia 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 200: UAE Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 201: UAE Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 202: UAE 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 203: UAE Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 204: UAE Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 205: UAE 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 207: Rest of Middle East Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 208: Rest of Middle East 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 210: Rest of Middle East Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 211: Rest of Middle East 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
AFRICA
Postmenopausal Osteoporosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 212: Africa Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 213: Africa Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 214: Africa 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
TABLE 215: Africa Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 216: Africa Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 217: Africa 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030